Details:

Alternative Title:
Emerg Infect Dis
Publisher's site:
http://dx.doi.org/10.3201/eid2006.131842
Personal Author:
Blair, Janis E. ; Chang, Yu-Hui H. ; Cheng, Meng-Ru ; Vaszar, Laszlo T. ; Vikram, Holenarasipur R. ; ... More +
Blair, Janis E. ; Chang, Yu-Hui H. ; Cheng, Meng-Ru ; Vaszar, Laszlo T. ; Vikram, Holenarasipur R. ; Orenstein, Robert ; Kusne, Shimon ; Ho, Stanford ; Seville, Maria T. ; Parish, James M. ; Less -
Description:
In Arizona, USA, primary pulmonary coccidioidomycosis accounts for 15%-29% of community-acquired pneumonia. To determine the evolution of symptoms and changes in laboratory values for patients with mild to moderate coccidioidomycosis during 2010-2012, we conducted a prospective 24-week study of patients with primary pulmonary coccidioidomycosis. Of the 36 patients, 16 (44%) were men and 33 (92%) were White. Median age was 53 years, and 20 (56%) had received antifungal treatment at baseline. Symptom scores were higher for patients who received treatment than for those who did not. Median times from symptom onset to 50% reduction and to complete resolution for patients in treatment and nontreatment groups were 9.9 and 9.1 weeks, and 18.7 and 17.8 weeks, respectively. Median times to full return to work were 8.4 and 5.7 weeks, respectively. One patient who received treatment experienced disseminated infection. For otherwise healthy adults with acute coccidioidomycosis, convalescence was prolonged, regardless of whether they received antifungal treatment.
Subject:
[+]
Acute Pulmonary Coccidioidomycosis
Antifungal Therapy
Coccidioides
Coccidioidomycosis
Community-acquired Pneumonia
Fungi
Research

Source:
Emerg Infect Dis. 20(6):983-990. ;
Document Type:
Journal Article ;
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:e622ce41585c0c718ca57451cb467e3e008b9c70f72000de541139d78b56720e
File Type:

Supporting Files

• 	13-1842-F1.gif	gif
  	13-1842-F1.jpg	jpeg
  	13-1842-F2.gif	gif
  	13-1842-F2.jpg	jpeg
  	13-1842.nxml	txt
  	license.txt	txt

More +